Showing 15 posts of 41 posts found.

glaxosmithkline building

GSK and Vir agree deal worth $645m for influenza and respiratory treatments

February 18, 2021
GSK, Vaccine, flu, influenze, vir

GSK and Vir Biotechnology have extended their collaboration in a deal that could be worth up to $645 million, in …


COVID-19 has caused over three times more deaths than flu or pneumonia in England and Wales

October 8, 2020
Medical Communications, Research and Development COVID-19, UK, flu

Newly released data has revealed that COVID-19 has resulted in many more deaths than influenza or pneumonia in England and …

New swine flu with pandemic potential identified in China

June 30, 2020
Manufacturing and Production flu, flu pandemic, swine flu

A new strain of flu has emerged in pigs in China, with scientists warning it has pandemic potential. Researchers call …


New findings on influenza could help improve cancer treatments

March 20, 2020
Manufacturing and Production, Medical Communications Cancer, cancer treatments, flu, flu treatments, influenza

A new study into how the body fights influenza could help improve cancer immunotherapies. Researchers at the Fox Chase Cancer …


FDA approves first adjuvanted quadrivalent flu vaccine in over-65s

February 24, 2020
Sales and Marketing FDA, flu, influenza, pharma, seqirus

The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) …


FDA approves Sanofi’s quadrivalent flu vaccine for over-65s

November 6, 2019
Research and Development, Sales and Marketing FDA, Fluzone, Sanofi, flu, influenza, pharma

Sanofi’s quadrivalent influenza vaccine Fluzone High Dose has secured FDA approval in adult patients over the age of 65 for …


FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza

October 18, 2019
Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma

Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …


Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial

September 2, 2019
Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma

Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …

Roche’s Xofluza proves non-inferior to Tamiflu in children with flu

July 3, 2019
Research and Development Roche, Tamiflu, flu, pharma

Roche has unveiled new Phase 3 data indicating that Xofluza (baloxavir marboxil) was well-tolerated and of comparable efficacy to its …


Beating the flu

February 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus

On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …


Seqirus secures first cell-based quadrivalent influenza vaccine approval in Europe

January 14, 2019
Sales and Marketing Europe, Flucelvax, flu, influenza, pharma, seqirus

Seqirus has made it known that its new cell-based seasonal influenza vaccine Flucelvax Tetra has been approved by the European …

Children should be given flu vaccine to protect older people

December 21, 2018
Medical Communications epidemiology, flu, health, public health, vaccines

Parents are being urged to give their children the flu vaccine in order to protect ‘older people’ from the potentially …

Probiotics have no effect on children with gastroenteritis, study shows

November 22, 2018
Research and Development children, flu, gastroenteritis, probiotics, research

Despite the claims of marketing campaigns and advertisements, probiotics have no effect on gastroenteritis on children, according to a new …

Vaccine coverage falls by 6.2% since last year

October 29, 2018
Sales and Marketing CDC, flu, influenza, vaccine coverage, vaccines

Despite the severity of the flu season, just 37.1% of American adults received the flu vaccine this year, according to …


First novel, single-dose flu drug approved in US in almost 20 years

October 25, 2018
Sales and Marketing FDA, Shionogi, Xofluza, flu, influenza, pharma

The FDA has announced that it has approved the first single-dose flu drug with a novel mechanism of action in …

Latest content